News

Public · Published

Precigen 3Q 2026: Revenue $74.15M, Net income $35.77M, EPS $0.08— 10-Q Summary

Precigen reported third-quarter 2026 revenue of $74.15 million and net income of $35.77 million, compared with $2.92 million in revenue and a $325.34 million net loss a year earlier. Diluted earnings per share were $0.08, versus a loss of $1.06 per share.

Published:

Updated:

What happened

Precigen reported third-quarter 2026 revenue of $74.15 million and net income of $35.77 million, compared with $2.92 million in revenue and a $325.34 million net loss a year earlier. Diluted earnings per share were $0.08, versus a loss of $1.06 per share.

Confirmed

Global impact / market context

The sharp improvement in reported revenue and earnings indicates a much stronger quarter than the prior-year period. Papzimeos sales are identified as the near-term revenue driver, so continued commercial growth could support company income, while a slowdown would leave results more dependent on its early-stage pipeline.

Analyst inference

Precigen says Papzimeos generated $148.0 million in the first nine months of 2026 as U.S. sales ramped after FDA approval. Its continued contribution, alongside regulatory review and clinical studies, links future results to product sales and development progress rather than the quarter’s figures alone.

Analyst inference

What to watch

  1. Track Papzimeos sales in later reporting periods: the article says the product is expected to drive most near-term revenue, making its commercial growth important to overall results. Analyst inference
  2. Watch the EMA’s review of the Papzimeos marketing application; the article reports the review is underway, but gives no decision date or outcome. Confirmed
  3. Follow enrollment in the open-label adult retreatment study and progress in the listed Phase 2 trials, since delays or results could shape future development spending and revenue prospects. Analyst inference

Evidence

  • Original source link unavailable